Literature DB >> 17234658

Role of the renin-angiotensin system in ventilator-induced lung injury: an in vivo study in a rat model.

Jih-Shuin Jerng1, Yu-Chiao Hsu, Huey-Dong Wu, Hong-Zhen Pan, Hao-Chien Wang, Chia-Tung Shun, Chong-Jen Yu, Pan-Chyr Yang.   

Abstract

BACKGROUND: Injurious mechanical ventilation can cause a pro-inflammatory reaction in the lungs. Recent evidence suggests an association of the renin-angiotensin system (RAS) with lung inflammation. A study was undertaken to investigate the pathogenic role of the RAS in ventilator-induced lung injury (VILI) and to determine whether VILI can be attenuated by angiotensin converting enzyme (ACE) inhibition.
METHODS: Male Sprague-Dawley rats were mechanically ventilated for 4 h with low (7 ml/kg) or high (40 ml/kg) tidal volumes; non-ventilated rats were used as controls. Lung injury and inflammation were measured by the lung injury score, protein leakage, myeloperoxidase activity, pro-inflammatory cytokine levels and nuclear factor (NF)-kappaB activity. Expression of the RAS components was also assessed. Some rats were pretreated with the ACE inhibitor captopril (10 mg/kg) for 3 days or received a concomitant infusion with losartan or PD123319 (type 1 or type 2 angiotensin II receptor antagonist) during mechanical ventilation to assess possible protective effects on VILI.
RESULTS: In the high-volume group (n=6) the lung injury score, bronchoalveolar lavage fluid protein concentration, pro-inflammatory cytokines and NF-kappaB activities were significantly increased compared with controls (n=6). Lung tissue angiotensin II levels and mRNA levels of angiotensinogen and type 1 and type 2 angiotensin II receptors were also significantly increased in the high-volume group. Pretreatment with captopril or concomitant infusion with losartan or PD123319 in the high-volume group attenuated the lung injury and inflammation (n=6 for each group).
CONCLUSIONS: The RAS is involved in the pathogenesis of ventilator-induced lung injury. ACE inhibitor or angiotensin receptor antagonists can attenuate VILI in this rat model.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17234658      PMCID: PMC2117227          DOI: 10.1136/thx.2006.061945

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  35 in total

1.  Angiotensin II activates nuclear transcription factor-kappaB through AT1 and AT2 receptors.

Authors:  Gunter Wolf; Ulrich Wenzel; Kevin D Burns; Raymond C Harris; Rolf A K Stahl; Friedrich Thaiss
Journal:  Kidney Int       Date:  2002-06       Impact factor: 10.612

2.  Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney.

Authors:  Marta Ruiz-Ortega; Mónica Ruperez; Oscar Lorenzo; Vanesa Esteban; Julia Blanco; Sergio Mezzano; Jesus Egido
Journal:  Kidney Int Suppl       Date:  2002-12       Impact factor: 10.545

Review 3.  Inflammation and angiotensin II.

Authors:  Yusuke Suzuki; Marta Ruiz-Ortega; Oscar Lorenzo; Monica Ruperez; Vanesa Esteban; Jesus Egido
Journal:  Int J Biochem Cell Biol       Date:  2003-06       Impact factor: 5.085

4.  NF-kappaB-dependent increase in intrarenal angiotensin II induced by proteinuria.

Authors:  Osamu Takase; Takeshi Marumo; Naohiko Imai; Junichi Hirahashi; Atsushi Takayanagi; Keiichi Hishikawa; Matsuhiko Hayashi; Nobuyoshi Shimizu; Toshiro Fujita; Takao Saruta
Journal:  Kidney Int       Date:  2005-08       Impact factor: 10.612

5.  Transcription factor NF-kappa B is necessary for up-regulation of type 1 angiotensin II receptor mRNA in rat cardiac fibroblasts treated with tumor necrosis factor-alpha or interleukin-1 beta.

Authors:  Randy T Cowling; Devorah Gurantz; JianFeng Peng; Wolfgang H Dillmann; Barry H Greenberg
Journal:  J Biol Chem       Date:  2001-10-12       Impact factor: 5.157

Review 6.  Ventilator-induced injury: from barotrauma to biotrauma.

Authors:  L N Tremblay; A S Slutsky
Journal:  Proc Assoc Am Physicians       Date:  1998 Nov-Dec

7.  Effect of simultaneous blockade of AT1 and AT2 receptors on the NFkappaB pathway and renal inflammatory response.

Authors:  Vanesa Esteban; Mónica Ruperez; Juan Rodriguez Vita; Elsa Sanchez López; Sergio Mezzano; Juan José Plaza; Jesús Egido; Marta Ruiz-Ortega
Journal:  Kidney Int Suppl       Date:  2003-10       Impact factor: 10.545

8.  Differential effects of ebselen on neutrophil recruitment, chemokine, and inflammatory mediator expression in a rat model of lipopolysaccharide-induced pulmonary inflammation.

Authors:  El-Bdaoui Haddad; Kerryn McCluskie; Mark A Birrell; Dominika Dabrowski; Michela Pecoraro; Steve Underwood; Bei Chen; George T De Sanctis; Steve E Webber; Martyn L Foster; Maria G Belvisi
Journal:  J Immunol       Date:  2002-07-15       Impact factor: 5.422

9.  Interferon-gamma enhances the pulmonary CXC chemokine response to intratracheal lipopolysaccharide challenge.

Authors:  Ping Zhang; Lee J Quinton; Gregory J Bagby; Warren R Summer; Steve Nelson
Journal:  J Infect Dis       Date:  2002-12-13       Impact factor: 5.226

10.  Angiotensin-converting enzyme 2 protects from severe acute lung failure.

Authors:  Yumiko Imai; Keiji Kuba; Shuan Rao; Yi Huan; Feng Guo; Bin Guan; Peng Yang; Renu Sarao; Teiji Wada; Howard Leong-Poi; Michael A Crackower; Akiyoshi Fukamizu; Chi-Chung Hui; Lutz Hein; Stefan Uhlig; Arthur S Slutsky; Chengyu Jiang; Josef M Penninger
Journal:  Nature       Date:  2005-07-07       Impact factor: 49.962

View more
  23 in total

1.  Inhibition of poly(adenosine diphosphate-ribose) polymerase attenuates ventilator-induced lung injury.

Authors:  Rosanna Vaschetto; Jan W Kuiper; Shyh Ren Chiang; Jack J Haitsma; Jonathan W Juco; Stefan Uhlig; Frans B Plötz; Francesco Della Corte; Haibo Zhang; Arthur S Slutsky
Journal:  Anesthesiology       Date:  2008-02       Impact factor: 7.892

2.  LPS-stimulated cytokine production in type I cells is modulated by the renin-angiotensin system.

Authors:  Mandi H Wong; Olivia C Chapin; Meshell D Johnson
Journal:  Am J Respir Cell Mol Biol       Date:  2011-12-28       Impact factor: 6.914

Review 3.  Do soluble mediators cause ventilator-induced lung injury and multi-organ failure?

Authors:  Thomas Jaecklin; Gail Otulakowski; Brian P Kavanagh
Journal:  Intensive Care Med       Date:  2010-03-16       Impact factor: 17.440

4.  Ventilator-induced inflammatory response in lipopolysaccharide-exposed rat lung is mediated by angiotensin-converting enzyme.

Authors:  Roelie M Wösten-van Asperen; René Lutter; Patricia A C Specht; Job B van Woensel; Chris M van der Loos; Sandrine Florquin; Burkhard Lachmann; Albert P Bos
Journal:  Am J Pathol       Date:  2010-03-19       Impact factor: 4.307

Review 5.  The Impact of ACE and ACE2 Gene Polymorphisms in Pulmonary Diseases Including COVID-19.

Authors:  Iphigenia Gintoni; Maria Adamopoulou; Christos Yapijakis
Journal:  In Vivo       Date:  2022 Jan-Feb       Impact factor: 2.155

6.  LPS-induced effects on angiotensin I-converting enzyme expression and shedding in human pulmonary microvascular endothelial cells.

Authors:  M I Hermanns; A M Müller; M Tsokos; C J Kirkpatrick
Journal:  In Vitro Cell Dev Biol Anim       Date:  2013-10-29       Impact factor: 2.416

Review 7.  A hypothesis for pathobiology and treatment of COVID-19: The centrality of ACE1/ACE2 imbalance.

Authors:  Krishna Sriram; Paul A Insel
Journal:  Br J Pharmacol       Date:  2020-05-22       Impact factor: 8.739

8.  GABA receptor ameliorates ventilator-induced lung injury in rats by improving alveolar fluid clearance.

Authors:  Narendranath Reddy Chintagari; Lin Liu
Journal:  Crit Care       Date:  2012-12-12       Impact factor: 9.097

9.  Crucial Role of PLGA Nanoparticles in Mitigating the Amiodarone-Induced Pulmonary Toxicity.

Authors:  Amira Motawea; Dalia Alsaied Moustafa Ahmed; Ahmed A El-Mansy; Noha Mohamed Saleh
Journal:  Int J Nanomedicine       Date:  2021-07-08

10.  Theoretical Assessment of Therapeutic Effects of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors on COVID-19.

Authors:  Azadeh Khalili; Hosein Karim; Gholamreza Bayat
Journal:  Iran J Med Sci       Date:  2021-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.